Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Adaptive Biotechnologies's Business Segments
Adaptive Biotechnologies's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
2
Largest Segment
Mrd Business Segment
Total Revenue
$ 72
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Mrd Business Segment92.5%
- Immune Medicine Business7.5%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Mrd Business Segment | $ 66 | 92.5% |
| Immune Medicine Business | $ 5 | 7.5% |
Revenue by Product & Service Category - Q2 FY2026
- Service and Licensing Revenue7.5%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service and Licensing Revenue | $ 5 | 7.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is a biotechnology company that specializes in the field of immune-driven medicine.
Founded in 2009 by Chad Robins and Harlan Robins, the Seattle-based company is focused on developing procedures and technologies to decode the immune system to help diagnose, manage, and treat various diseases.
Adaptive Biotechnologies' flagship product is its immune profiling technology, which uses next-generation sequencing and machine learning algorithms to read the genetic makeup of a patient's immune system.
This technology allows the company to develop highly personalized, targeted therapies for various types of cancers and autoimmune disorders.
The company has built a proprietary database of immune system data that is the largest and most diverse in the world.
This database is continuously growing through partnerships with biopharmaceutical companies and academic institutions.
Adaptive Biotechnologies also collaborates with researchers and physicians around the globe to advance the understanding of the immune system and develop new therapies.
Adaptive Biotechnologies has partnered with many pharmaceutical and biotech companies, such as Genentech and Amgen, to develop new diagnostic and therapeutic products.
The company has also received funding and investment from high-profile organizations such as Microsoft, which has invested in the company's technology for use in molecular diagnostics.
Some of the diseases that Adaptive Biotechnologies is exploring include cancer, autoimmune disorders, infectious diseases, and neurodegenerative diseases.
The company is also involved in developing COVID-19 testing products and has partnered with Microsoft to develop a blood-based test that can identify the immune response to the virus.
Adaptive Biotechnologies has received recognition for its innovative technology and research.
In 2019, the company was named a Technology Pioneer by the World Economic Forum, which honors companies that are using technology to solve global issues.
In summary, Adaptive Biotechnologies Corporation is a leading biotechnology company focused on developing innovative immune-driven technologies to diagnose, manage, and treat various diseases.
The company's immune profiling technology, proprietary database, and partnerships with biopharmaceutical companies and academic institutions have made it a leader in the field of immune-driven medicine.
Founded in 2009 by Chad Robins and Harlan Robins, the Seattle-based company is focused on developing procedures and technologies to decode the immune system to help diagnose, manage, and treat various diseases.
Adaptive Biotechnologies' flagship product is its immune profiling technology, which uses next-generation sequencing and machine learning algorithms to read the genetic makeup of a patient's immune system.
This technology allows the company to develop highly personalized, targeted therapies for various types of cancers and autoimmune disorders.
The company has built a proprietary database of immune system data that is the largest and most diverse in the world.
This database is continuously growing through partnerships with biopharmaceutical companies and academic institutions.
Adaptive Biotechnologies also collaborates with researchers and physicians around the globe to advance the understanding of the immune system and develop new therapies.
Adaptive Biotechnologies has partnered with many pharmaceutical and biotech companies, such as Genentech and Amgen, to develop new diagnostic and therapeutic products.
The company has also received funding and investment from high-profile organizations such as Microsoft, which has invested in the company's technology for use in molecular diagnostics.
Some of the diseases that Adaptive Biotechnologies is exploring include cancer, autoimmune disorders, infectious diseases, and neurodegenerative diseases.
The company is also involved in developing COVID-19 testing products and has partnered with Microsoft to develop a blood-based test that can identify the immune response to the virus.
Adaptive Biotechnologies has received recognition for its innovative technology and research.
In 2019, the company was named a Technology Pioneer by the World Economic Forum, which honors companies that are using technology to solve global issues.
In summary, Adaptive Biotechnologies Corporation is a leading biotechnology company focused on developing innovative immune-driven technologies to diagnose, manage, and treat various diseases.
The company's immune profiling technology, proprietary database, and partnerships with biopharmaceutical companies and academic institutions have made it a leader in the field of immune-driven medicine.
Adaptive Biotechnologies Corporation is a pioneering biotechnology company focused on decoding the human immune system through advanced immunosequencing technologies. Their offerings span various segments, products, and services that play a critical role in enhancing disease diagnosis and treatment, particularly in the realms of oncology, infectious diseases, and autoimmune disorders.
Segments
Adaptive Biotechnologies operates primarily in two key segments:
1. Clinical Diagnostics:
This segment focuses on providing sophisticated diagnostic tools that facilitate the detection, diagnosis, and monitoring of diseases. Their products in this category are designed to meet clinical needs, aiding healthcare professionals in critical decision-making, treatment planning, and patient management.
- immunoSEQ Dx: A pivotal product in this segment, immunoSEQ Dx is an FDA-cleared clinical immunosequencing assay that provides vital information regarding patients’ immune responses, particularly in the context of cancer and other serious diseases.
2. Life Sciences Research:
Here, Adaptive Biotechnologies extends its capabilities to academic, government, and commercial organizations, contributing to a deeper understanding of the immune system and aiding in the development of innovative therapeutics. This segment supports researchers by providing cutting-edge tools and data.
- immunoSEQ Technology: A research-use-only assay that allows scientists to explore the diversity and frequency of T-cell and B-cell receptors, facilitating further research into immune responses and potential therapies.
Products
Adaptive Biotechnologies has developed an arsenal of products leveraging its immunosequencing technology:
1. immunoSEQ Dx:
- A clinical immunosequencing assay diagnostic test that has obtained FDA clearance. It is instrumental in diagnosing and monitoring a wide range of diseases, including hematologic malignancies, solid tumors, infectious diseases, and autoimmune disorders. This product helps clinicians understand patients immune responses and tailor treatments accordingly.
2. immunoSEQ Research Products:
- These research-use-only assays provide capabilities to assess the diversity and frequency of T-cell and B-cell receptors in various samples. This product is valuable to researchers aiming to elucidate immune mechanisms and develop new therapeutic strategies.
3. clonoSEQ:
- A specialized assay designed for minimal residual disease (MRD) detection in blood cancers, including leukemia and lymphoma. clonoSEQ helps oncologists monitor patients for relapse after treatment by detecting low levels of cancer-related cells that may remain undetectable through standard methods.
Services
In addition to advanced products, Adaptive Biotechnologies offers a range of services designed to support clinicians and researchers:
1. Clinical Testing Services:
- This encompasses comprehensive clinical-grade testing such as immunoSEQ Dx and clonoSEQ that provide insights into patient immune profiles and disease states, facilitating accurate diagnosis and monitoring for various conditions.
2. Research and Development Services:
- These services cater to academic and commercial entities looking to leverage immunosequencing technologies. Adaptive Biotechnologies collaborates on R&D projects, providing expertise and access to its advanced tools, including immunoSEQ Technology.
3. Sample Preparation and Sequencing Services:
- This includes specialized preparation and sequencing services that ensure the integrity and quality of samples for immunosequencing. These services are critical for researchers who need precise and accurate data to draw meaningful conclusions from their experiments.
Conclusion
Adaptive Biotechnologies Corporation stands at the forefront of immunology innovation, offering a comprehensive suite of products and services that empower researchers and clinicians alike. With its robust platform in immune medicine, the company continues to redefine approaches to diagnosing and treating diseases, providing invaluable insights into the complex functioning of the human immune system. By fostering advancements in both clinical diagnostics and life sciences research, Adaptive Biotechnologies is playing a pivotal role in the future landscape of personalized medicine and targeted therapy developments.
Segments
Adaptive Biotechnologies operates primarily in two key segments:
1. Clinical Diagnostics:
This segment focuses on providing sophisticated diagnostic tools that facilitate the detection, diagnosis, and monitoring of diseases. Their products in this category are designed to meet clinical needs, aiding healthcare professionals in critical decision-making, treatment planning, and patient management.
- immunoSEQ Dx: A pivotal product in this segment, immunoSEQ Dx is an FDA-cleared clinical immunosequencing assay that provides vital information regarding patients’ immune responses, particularly in the context of cancer and other serious diseases.
2. Life Sciences Research:
Here, Adaptive Biotechnologies extends its capabilities to academic, government, and commercial organizations, contributing to a deeper understanding of the immune system and aiding in the development of innovative therapeutics. This segment supports researchers by providing cutting-edge tools and data.
- immunoSEQ Technology: A research-use-only assay that allows scientists to explore the diversity and frequency of T-cell and B-cell receptors, facilitating further research into immune responses and potential therapies.
Products
Adaptive Biotechnologies has developed an arsenal of products leveraging its immunosequencing technology:
1. immunoSEQ Dx:
- A clinical immunosequencing assay diagnostic test that has obtained FDA clearance. It is instrumental in diagnosing and monitoring a wide range of diseases, including hematologic malignancies, solid tumors, infectious diseases, and autoimmune disorders. This product helps clinicians understand patients immune responses and tailor treatments accordingly.
2. immunoSEQ Research Products:
- These research-use-only assays provide capabilities to assess the diversity and frequency of T-cell and B-cell receptors in various samples. This product is valuable to researchers aiming to elucidate immune mechanisms and develop new therapeutic strategies.
3. clonoSEQ:
- A specialized assay designed for minimal residual disease (MRD) detection in blood cancers, including leukemia and lymphoma. clonoSEQ helps oncologists monitor patients for relapse after treatment by detecting low levels of cancer-related cells that may remain undetectable through standard methods.
Services
In addition to advanced products, Adaptive Biotechnologies offers a range of services designed to support clinicians and researchers:
1. Clinical Testing Services:
- This encompasses comprehensive clinical-grade testing such as immunoSEQ Dx and clonoSEQ that provide insights into patient immune profiles and disease states, facilitating accurate diagnosis and monitoring for various conditions.
2. Research and Development Services:
- These services cater to academic and commercial entities looking to leverage immunosequencing technologies. Adaptive Biotechnologies collaborates on R&D projects, providing expertise and access to its advanced tools, including immunoSEQ Technology.
3. Sample Preparation and Sequencing Services:
- This includes specialized preparation and sequencing services that ensure the integrity and quality of samples for immunosequencing. These services are critical for researchers who need precise and accurate data to draw meaningful conclusions from their experiments.
Conclusion
Adaptive Biotechnologies Corporation stands at the forefront of immunology innovation, offering a comprehensive suite of products and services that empower researchers and clinicians alike. With its robust platform in immune medicine, the company continues to redefine approaches to diagnosing and treating diseases, providing invaluable insights into the complex functioning of the human immune system. By fostering advancements in both clinical diagnostics and life sciences research, Adaptive Biotechnologies is playing a pivotal role in the future landscape of personalized medicine and targeted therapy developments.